| Nov 13 |
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
|
| Nov 12 |
Artelo Biosciences GAAP EPS of -$0.35 beats by $0.44
|
| Nov 12 |
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 5 |
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
|
| Oct 9 |
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
|
| Sep 4 |
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 13 |
Artelo Biosciences GAAP EPS of -$0.75
|
| Aug 13 |
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 15 |
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study
|
| Jul 15 |
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
|
